LONDON, UK — November 30, 2020 — Life Science Newswire – Generis, a leader in content and information management systems for regulated industries, announces its strategic partnership with Cognizant, a global provider of information technology, consulting, and business process services, to deliver innovative information management solutions for life sciences.
This partnership will see Cognizant leverage Generis' flagship product, the CARA Life Science Platform, to enable clients to streamline their business processes on one comprehensive workspace that covers: RIM / regulatory and quality / QMS and safety / PV and clinical, as well as enterprise-wide functionality such as component-based / structured content authoring.
CARA is an innovative enterprise workspace designed specifically for life sciences which offers a simple, unified way of working with business-critical content and information. The solution enables rapid, codeless implementation of regulated business processes for managing content and data securely and seamlessly across the business, with connectivity to modern productivity tools (e.g., Office 365, DocuSign, Slack, Google Docs/Drive, SAP, and many others). With a standardization of processes across the business, CARA allows organizations to ensure consistent rules for security, versioning, life cycles, and workflows. The platform delivers secure, versatile, and scalable solutions both in the cloud as SaaS or on premise.
"We are delighted to be working with such a forward-thinking organization. Cognizant understands the business problems that our mutual customers face, and how to address those in a way that goes beyond the standard IT implementation partner approach," said James Kelleher, CEO of Generis. "This strategic partnership will enable our existing and new customers to make the most of the possibilities within the CARA platform."
CARA is already widely deployed in the pharmaceutical, biotech, medical device, and other life sciences industries where strict regulatory compliance must be maintained. Customers include 60 percent of the Top 20 largest global life science companies as well as over 500,000 users globally.